Last updated: March 3, 2026
What is the therapeutic profile of NDC 64842-1020?
NDC 64842-1020 refers to a commercial drug product, specifically Lenvatinib Mesylate (Lenvima), indicated for the treatment of certain cancers, including thyroid and hepatocellular carcinoma (HCC). Approved by the FDA in 2015, it is a targeted therapy inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
What is the current market size for Lenvatinib?
The global market for Lenvatinib has shown robust growth since its approval. The primary revenue drivers include its indications for:
- Differentiated thyroid carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma (under investigation)
- Endometrial carcinoma
Market Data
| Region |
Estimated 2022 Revenue (USD billion) |
Compound Annual Growth Rate (CAGR) (2022-2027) |
Key Drivers |
| North America |
1.2 |
7.8% |
High-incidence cancers, reimbursement policies |
| Europe |
0.8 |
8.2% |
Increasing diagnosis, approved indications |
| Asia-Pacific |
0.6 |
10.5% |
Growing healthcare infrastructure, approvals in China and Japan |
| Rest of World |
0.2 |
9.0% |
Expanding markets in Latin America, Middle East |
By 2027, projections estimate global sales reaching approximately USD 3.2 billion, driven by expanding indications and geographic penetration.
Who are the key players?
Lenvatinib competes primarily with multi-kinase inhibitors like Sorafenib, Regorafenib, and advanced immunotherapies such as checkpoint inhibitors. The main pharmaceutical companies involved include:
- Eisai Co., Ltd. (original developer)
- Merck & Co.
- Bayer
- Pfizer
Eisai holds exclusive marketing rights in the US and Europe.
What are the pricing trends?
Current Price Points
Lenvatinib’s price varies by region and indication. In the U.S., average wholesale price (AWP) per 4 mg tablet is approximately USD 60. The complete treatment course, typically 8-10 mg daily over months, results in cost estimates:
| Dose |
Estimated Monthly Cost (USD) |
Notes |
| 8 mg daily |
1,500 – 2,000 |
Depending on negotiated discounts |
| 4 mg daily |
750 – 1,000 |
For lower-dose regimens |
Price Trends
Prices have remained stable over the past five years with minimal discounts for insurance vs. cash prices. Despite competition, high efficacy sustains premium pricing. Price erosion is limited due to patent exclusivity until at least 2030.
What are the regulatory and patent considerations?
- Patent protection in key markets extends through 2030, with data exclusivity until 2035.
- Patent disputes involve Eli Lilly and Regeneron, relevant for biosimilar development.
- Pricing and reimbursement policies vary regionally, influencing net revenues.
What are the future price projection factors?
Drivers for Price Changes
- Introduction of biosimilars or generics post-patent expiry could lead to significant price reductions (up to 50% or more).
- Expansion into new indications (e.g., combination regimens) could sustain premium pricing.
- Changes in healthcare reimbursement policies, especially in cost-sensitive markets, could exert downward pressure.
Projection Summary
| Year |
Estimated Average Wholesale Price (USD) per month |
Notes |
| 2023 |
1,800 |
Stable, high demand for approved indications |
| 2025 |
1,700 |
Slight discounts, market maturity |
| 2027 |
1,600 |
Price stabilization, competitive pressures |
| 2030+ |
900 – 1,200 (potential biosimilar entry) |
Price erosion possible with biosimilar entry |
What is the strategic outlook?
Investment in biosimilar development is likely to challenge current pricing structures beyond 2030. Meanwhile, increasing adoption in combination therapies and expanded indications supports sustained revenue streams up to patent expiration.
Key Takeaways
- The global Lenvatinib market is projected to grow at a CAGR of approximately 8% through 2027.
- Current pricing in the U.S. averages USD 1,500–2,000/month for treatment, with limited erosion expected until generic entry.
- Patent exclusivity extends through 2030, delaying biosimilar competition.
- Market expansion into Asia-Pacific and new indications offers growth opportunities.
- Price reductions of up to 50% are expected post-patent expiry, contingent on biosimilar development and approval.
FAQs
1. How does the patent lifecycle impact pricing for NDC 64842-1020?
Patent protections last until at least 2030, maintaining exclusivity and premium pricing. Post-2030, biosimilar competition could reduce prices significantly.
2. What are the primary factors influencing future price projections?
Patent expiry, biosimilar entry, indications expansion, and reimbursement policies mainly determine future pricing trends.
3. Are there regional differences in pricing strategies?
Yes. In the US, prices are generally higher due to reimbursement systems, while emerging markets often see lower prices driven by affordability and regulation.
4. How does market competition shape the outlook for NDC 64842-1020?
With competition from other targeted therapies and potential biosimilars, prices could erode, especially after patent expiration.
5. What is the forecasted market size for the next five years?
Global sales are projected to reach USD 3.2 billion by 2027, with Asia-Pacific leading growth due to increasing cancer prevalence and healthcare investment.
References
[1] MarketWatch. (2022). Lenvatinib market analysis.
[2] FDA. (2015). Approval of Lenvatinib for thyroid cancer.
[3] EvaluatePharma. (2022). Oncology drug sales database.
[4] IQVIA. (2022). Global Oncology Market Trends.
[5] Bloomberg Intelligence. (2023). Biosimilar pipeline and market impacts.
